Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vivos Therapeutics, Inc.VVOS · Entity 8396 | Director | June 20, 2024 | June 29, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vivos Therapeutics, Inc.
Report date June 20, 2024 · Filed June 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2029-06-20 | Direct | 7,067 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 4,000 · Balance 7,067 F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 20, 2024 Filed Jun 29, 2024 00:53 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 4,000 | $2.38 Strike: $2.38 | $9,520.00 |
DisclosureSEC source: 0001493152-24-025690 · ownership.xml · derivative · entry 1 Lindsay Mark F. · CIK 0001835542 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,067 Underlying: Common Stock · 4,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024. Read SEC document |
| December 23, 2022 Filed Dec 29, 2022 02:45 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.48 Strike: $0.48 | $14,400.00 |
DisclosureSEC source: 0001493152-22-036728 · ownership.xml · derivative · entry 1 Lindsay Mark F. · CIK 0001835542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,667 Underlying: Common Stock · 76,667 shares Expires 2027-12-23 F1 · derivative.exercise_date: 30,000 stock options granted on December 23, 2022. One-half vested immediately and one-eighth vests quarterly every three months through December 23, 2023. Read SEC document |
| August 05, 2021 Filed Aug 11, 2021 01:43 UTC | Vivos Therapeutics, Inc. VVOS · Entity 8396 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $2.72 Strike: $2.72 | $81,600.00 |
DisclosureSEC source: 0001493152-21-019249 · ownership.xml · derivative · entry 1 Lindsay Mark F. · CIK 0001835542 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,667 Underlying: Common Stock · 46,667 shares Expires 2026-08-05 F1 · derivative.exercise_date: 30,000 stock options granted on August 5, 2021. One-half vested immediately and one-eighth vests quarterly every three months through August 5, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.